Pharsight

1. Drug name - ISTURISA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835646	RECORDATI RARE	Organic compounds	Aug, 2026 (3 years from now)
US8314097	RECORDATI RARE	Organic compounds	Mar, 2029 (6 years from now)
US9434754	RECORDATI RARE	Use of an adrenal hormone-modifying agent	Jan, 2031 (8 years from now)
CN105440038A	RECORDATI RARE	Use Of An Adrenal Hormone-Modifying Agent	Feb, 2019 (3 years ago)
CN101248078B	RECORDATI RARE	Inhibition Of Aldosterone Synthase And Fused Imidazole Derivatives Of Aromatase	Aug, 2026 (3 years from now)
CN102408429A	RECORDATI RARE	Inhibition Of Aldosterone Synthase And Fused Imidazole And Derivatives Of Aromatase	Aug, 2026 (3 years from now)
CN101248078A	RECORDATI RARE	Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase	Aug, 2026 (3 years from now)
CN102408429B	RECORDATI RARE	Inhibition Of Aldosterone Synthase And Fused Imidazole Derivatives Of Aromatase	Aug, 2026 (3 years from now)
CN102711916B	RECORDATI RARE	Use Of An Adrenal Hormone-Modifying Agent	Jan, 2031 (8 years from now)
CN102711916A	RECORDATI RARE	Use Of An Adrenal Hormone-Modifying Agent	Jan, 2031 (8 years from now)
IN200800733P1	RECORDATI RARE	Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase	Aug, 2026 (3 years from now)
IN265497B	RECORDATI RARE	Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase	Aug, 2026 (3 years from now)
EP1919916B1	RECORDATI RARE	Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase	Aug, 2026 (3 years from now)
EP2256118B1	RECORDATI RARE	Condensed Imidazolo Derivatives For The Inhibition Of Aromatase And The Treatment Of Aldosterone Related Diseases	Aug, 2026 (3 years from now)
EP1919916A1	RECORDATI RARE	Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase	Aug, 2026 (3 years from now)
EP1919916B8	RECORDATI RARE	Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase	Aug, 2026 (3 years from now)
EP2256118A1	RECORDATI RARE	Condensed Imidazolo Derivatives For The Inhibition Of Aromatase And The Treatment Of Aldosterone Related Diseases	Aug, 2026 (3 years from now)
EP2523731A1	RECORDATI RARE	Use Of An Adrenal Hormone-Modifying Agent	Jan, 2031 (8 years from now)
EP2523731B1	RECORDATI RARE	Use Of An Adrenal Hormone-Modifying Agent	Jan, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862	RECORDATI RARE	Use of an adrenal hormone-modifying agent	Jan, 2031 (8 years from now)
US10143680	RECORDATI RARE	Pharmaceutical dosage forms	Jul, 2035 (12 years from now)
US10709691	RECORDATI RARE	Pharmaceutical dosage forms	Oct, 2035 (13 years from now)

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

Treatment: Cushing's disease

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 1MG BASE	TABLET;ORAL	Prescription
EQ 5MG BASE	TABLET;ORAL	Prescription
EQ 10MG BASE	TABLET;ORAL	Prescription

2. Drug name - NEOPROFEN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415337	RECORDATI RARE	Ibuprofen compositions and methods of making same	Mar, 2032 (9 years from now)

Drugs and Companies using IBUPROFEN LYSINE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

Strength	Dosage	Availability
EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	INJECTABLE;INTRAVENOUS	Prescription

3. Drug name - SIGNIFOR

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8299209	RECORDATI RARE	Pharmaceutical composition comprising cyclic somatostatin analogues	Dec, 2025 (3 years from now)
US7473761	RECORDATI RARE	Somatostatin analogues	Dec, 2026 (4 years from now)
CN1267451C	RECORDATI RARE	Somatostatin Analogues	Jul, 2021 (1 year, 2 months ago)
CN1446229A	RECORDATI RARE	Somatostatin Analogues	Jul, 2021 (1 year, 2 months ago)
CN1812997A	RECORDATI RARE	Pharmaceutical Composition	Jun, 2024 (1 year, 8 months from now)
CN1812997B	RECORDATI RARE	Parenteral Pharmaceutical Compositions Comprising Somatostatin Analogues	Jun, 2024 (1 year, 8 months from now)
IN200300143P4	RECORDATI RARE	Somatostatin Peptidomimetics	Jul, 2021 (1 year, 2 months ago)
IN204073B	RECORDATI RARE	Somatostatin Peptidomimetics	Jul, 2021 (1 year, 2 months ago)
IN200503498P4	RECORDATI RARE	Pharmaceutical Composition	Jun, 2024 (1 year, 8 months from now)
IN229591B	RECORDATI RARE	Parenteral Pharmaceutical Composition Comprising Somatostatin And Tartaric Acid	Jun, 2024 (1 year, 8 months from now)
EP1648934A2	RECORDATI RARE	Pharmaceutical Composition Comprising Cyclic Somatostatin Analogues	Jun, 2024 (1 year, 8 months from now)
EP1648934B1	RECORDATI RARE	Pharmaceutical Composition Comprising Cyclic Somatostatin Analogues	Jun, 2024 (1 year, 8 months from now)
EP1307486B1	RECORDATI RARE	Somatostatin Analogues	Jul, 2026 (3 years from now)
EP1307486A2	RECORDATI RARE	Somatostatin Analogues	Jul, 2026 (3 years from now)

Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription
EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription
EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

4. Drug name - SIGNIFOR LAR KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7473761	RECORDATI RARE	Somatostatin analogues	Dec, 2026 (4 years from now)
CN1267451C	RECORDATI RARE	Somatostatin Analogues	Jul, 2021 (1 year, 2 months ago)
CN1446229A	RECORDATI RARE	Somatostatin Analogues	Jul, 2021 (1 year, 2 months ago)
IN200300143P4	RECORDATI RARE	Somatostatin Peptidomimetics	Jul, 2021 (1 year, 2 months ago)
IN204073B	RECORDATI RARE	Somatostatin Peptidomimetics	Jul, 2021 (1 year, 2 months ago)
EP1307486B1	RECORDATI RARE	Somatostatin Analogues	Jul, 2026 (3 years from now)
EP1307486A2	RECORDATI RARE	Somatostatin Analogues	Jul, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822637	RECORDATI RARE	Somatostatin analogues	Aug, 2023 (10 months from now)
US7759308	RECORDATI RARE	Microparticles comprising somatostatin analogues	Oct, 2026 (4 years from now)
US9351923	RECORDATI RARE	Extended-release composition comprising a somatostatin derivative in microparticles	May, 2028 (5 years from now)

Drugs and Companies using PASIREOTIDE PAMOATE ingredient

Treatment: Method of treating acromegaly

Dosage: FOR SUSPENSION;INTRAMUSCULAR

Strength	Dosage	Availability
EQ 10MG BASE/VIAL	FOR SUSPENSION;INTRAMUSCULAR	Prescription
EQ 20MG BASE/VIAL	FOR SUSPENSION;INTRAMUSCULAR	Prescription
EQ 30MG BASE/VIAL	FOR SUSPENSION;INTRAMUSCULAR	Prescription
EQ 40MG BASE/VIAL	FOR SUSPENSION;INTRAMUSCULAR	Prescription
EQ 60MG BASE/VIAL	FOR SUSPENSION;INTRAMUSCULAR	Prescription

Pharsight

Drug Patents owned by Recordati Rare

1. Drug name - ISTURISA

2. Drug name - NEOPROFEN

3. Drug name - SIGNIFOR

4. Drug name - SIGNIFOR LAR KIT

availability in other generic markets.

Click on the highlighted region to filter.

Pharsight

Drug Patents owned by Recordati Rare

1. Drug name - ISTURISA

2. Drug name - NEOPROFEN

3. Drug name - SIGNIFOR

4. Drug name - SIGNIFOR LAR KIT

availability in other generic markets. Click on the highlighted region to filter.

availability in other generic markets.

Click on the highlighted region to filter.